Nexavar in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer. Cardiac ischemia and/or myocardial infarction may occur. Temporary or permanent discontinuation of Nexavar should be considered in patients who develop cardiac ischemia and/or myocardial infarction. An increased risk of bleeding may occur following Nexavar administration. If bleeding necessitates medical intervention, consider permanent discontinuation of Nexavar. continue reading below »
*Asia-Pacific (AP) Liver Cancer Study: A randomized, double-blind, placebo-controlled, multicenter, phase 3 study conducted in patients with advanced (unresectable or metastatic) HCC in China, Taiwan, and South Korea (N=226).
Reference: 1. Cheng AL, Yang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25-34.